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The sample size in the study was planned with 85% power, with the significance level of 5% for the detection of a difference between the 2 treatment groups for the anticipated ischemic event rates. The lower event rates and the concern about the safety of patients not undergoing percutaneous coronary intervention (PCI) as the initial treatment led to a change in the significance level for the final analysis of the incidence of ischemic events from 5% to 4.5%. Thus the 36% relative reduction in event was not statistically significant (P = .048) after adjustment for interim analysis.
Selection of low-risk patients
Nearly 60% of the patients in the AVERT trial were either asymptomatic or had only class I anginal symptoms with stable single-or double-vessel CAD with preserved left ventricular function (mean ejection fraction 61%). Such low-risk patients are likely to benefit from medical therapy compared with the interventional procedure because of the immediate risk of complications and procedure-related late events. 2 Hence the results of the AVERT trial cannot be extrapolated to patients with multivessel CAD or patients who need revascularization for symptom control or survival benefit.
Lack of ischemia-guided revascularization
Because the majority of the patients had either no symptoms or were minimally symptomatic and the fact that 40% of the patients had prior myocardial infarction (MI), the indication for PCI was not objectively shown in all. The benefit of revascularization may be undermined with the inclusion of patients who might have undergone revascularization in which the ischemic burden was either absent or minimal. 3 The inclusion of patients with coronary stenosis <70% for angioplasty further attests to this possibility.
Incomplete revascularization
As noted in the trial, 1 99 patients had single-vessel disease and 78 patients had double-vessel disease in the angioplasty group. This would imply that there were 255 target lesions. Considering those 11 patients who did not undergo revascularization, the target lesions needing revascularization would be 233 to 244, depending on whether the 11 patients had double-or singlevessel disease. Only 213 lesions underwent intervenThe proven efficacy of lipid-lowering therapy in favorably altering the natural history of coronary artery disease (CAD) has led to a recent comparison of aggressive lipid-lowering therapy versus percutaneous coronary revascularization with usual care in stable CAD (the Atorvastatin Versus Revascularization Treatment [AVERT] trial). 1 In this study, recently published in the New England Journal of Medicine, the authors concluded that in low-risk patients with stable CAD, aggressive lipid lowering is at least as effective as angioplasty and usual care in reducing the incidence of ischemic events. The conclusions of the study are thought-provoking and raise several questions. Is aggressive lipid-lowering therapy an alternative to revascularization treatment? Is the goal of super-low LDL cholesterol better than the current recommendation? What can and can't each therapy achieve? What is the goal of each therapy? Are the therapies complementary? We intend to address some of these issues with a critical review of the trial and the existing evidence.
Limitations of AVERT trial design and outcomes

Small sample size
By contemporary cardiology standards the sample size of 341 patients in the AVERT trial was incredibly small to make the kind of broad generalizations that the authors make. This is especially true because of the inclusion of 7 different variables that constituted part of the composite end point. In the AVERT trial, 177 patients were randomly assigned to angioplasty with usual care and 164 patients to aggressive lipid lowering with 80 mg atorvastatin. Baseline mean LDL cholesterol was approximately 140 mg/dL, and patients with aggressive lipid lowering achieved a 46% reduction in LDL cholesterol (mean 77 mg/dL) compared with an 18% reduction (mean 119 mg/dL) for the angioplasty group. The incidences of ischemic events as defined in the trial were reduced by 36% over an 18-month period (13% for patients receiving Atorvastatin Versus Revascularization Treatment (AVERT): Fact or fancy?
